Small extracellular vesicles and liver diseases: From diagnosis to therapy

Atsunori Tsuchiya, Kazuki Natsui, Yui Ishii, Yohei Koseki, Nobutaka Takeda, Kei Tomiyoshi, Fusako Yamazaki, Yuki Yoshida, Shuji Terai

Abstract

Extracellular vesicles (EVs), especially small EVs (sEVs) derived from liver cells, have been the focus of much attention in the normal physiology and pathogenesis of various diseases affecting the liver. sEVs are approximately 100 nm in size, enclosed within lipid bilayers, and are very stable. The lipids, proteins, and nucleic acids, including miRNAs, contained within these vesicles are known to play important roles in intercellular communication. This mini-review summarizes the application of sEVs. First, liver diseases and the related diagnostic markers are described, and the current active status of miRNA research in diagnosis of hepatocellular carcinoma (HCC) is reported. Second, the biodistribution and pharmacokinetics of sEVs are described, and the liver is highlighted as the organ with the highest accumulation of sEVs. Third, the relationship between sEVs and the pathogenesis of liver disorders is described with emphasis on the current active status of miRNA research in HCC recurrence and survival. Finally, the possibility of future therapy using sEVs from mesenchymal stem (stromal) cells for cirrhosis and other diseases is described.

Key Words: Small extracellular vesicles; Liver; cirrhosis; Hepatocellular carcinoma; Mesenchymal stem cells
**Core Tip:** Extracellular vesicles (EVs), especially small EVs (sEVs) derived from liver cells, have been the focus of much attention in the normal physiology and pathogenesis of various diseases affecting the liver. sEVs are approximately 100 nm in size, enclosed within lipid bilayers, and are very stable. The proteins and nucleic acids, including miRNAs, contained within these vesicles are known to play important roles in intercellular communication. This mini-review summarizes the application of sEVs in the diagnosis of liver diseases, along with their distribution post administration, their role in pathogenesis, and their potential therapeutic effects in hepatic disorders.

**INTRODUCTION**

The study of extracellular vesicles (EVs) is an active area of research. Recent evidence has established that these EVs are released not only by human cells, but also by plant, bacterial, and yeast cells[1]. EVs are sub-organellar entities that act as 'cargo' carriers that transmit information between cells thus exerting a variety of effects on biological activities. Since the vesicles released are unique to the cells that release them, they have been widely studied in diseases of various organs and systems, including diseases of the liver in the context of diagnosis, pathogenesis, and therapeutic applications[2-5]. In particular, small extracellular vesicles (sEVs; referred to as exosomes), with a particle size of approximately 100 nm, have garnered much attention in recent years[6-11].

Secretory vesicles were first described in the 1980s, and they have been referred to by a number of different names based on their size and cellular origin such as exosomes, ectosomes, microvesicles, shedding vesicles, apoptotic bodies, oncosomes, and prostasomes. The International Society for Extracellular Vesicles recommends the usage of extracellular vesicles as a general term for these entities. Small EVs (sEVs), or exosomes, are formed from early endosomes that are generated by endocytosis[12]. The late endosomes expand to form intraluminal membrane vesicles, also referred to as multivesicular bodies (MVBs), which then fuse with the plasma membrane and are released into the extracellular space. Secreted vesicles with a diameter of 30–200 nm are called sEVs or exosomes, and they are known to encapsulate a content of proteins, mRNAs, and miRNAs within a membrane composed of cholesterol, sphingomyelin, ceramide, and lipid rafts[13]. Although these vesicles vary between cells, there are common markers that characterize most exosomes including membrane transport and fusion proteins (GTPases, annexins, flotillin, etc.), heat shock proteins (HSP60, HSP70, HSP90, etc.), tetraspanins (CD9, CD63, CD81, etc.), MVB formation and transport proteins (TSG101, ALIX, Annexins, etc.), and cytoskeletal proteins (actin, tubulin, etc.[11-13]). sEVs can be important applications in the diagnosis and treatment of various diseases and malignancies, and their study can also contribute to the elucidation of the pathogenesis of these disease. For example, the stable inclusion of drugs within the lipid bilayers of sEVs creates novel therapeutic drug delivery systems that can be implied in the treatment of different diseases[13] (Figure 1).

Investigations on EVs are rapidly moving beyond basic research to clinical trials, and the global market of the diagnostic and treatment strategies that use sEVs, although still in its infancy, is expected to progress rapidly. This paper reviews the role of sEVs in the context of diagnosis, pathogenesis, and treatment of liver diseases.

**sEVs AND DIAGNOSIS OF LIVER DISEASES**

Although different types of EVs were studied in the context of liver disorders, in this report we focus mainly on the role sEVs in the pathogenesis, diagnosis, and treatment of liver diseases. sEVs in particular have been analyzed in various chronic liver diseases such as non-alcoholic steatohepatitis (NASH), alcoholic liver disease (ALD), viral hepatitis caused by hepatitis B virus (HBV) and hepatitis C virus (HCV), cirrhosis, acute liver disease, and hepatocellular carcinoma (HCC); and in various specimens including blood, urine, bile, and ascitic fluid[14]. There are various techniques that were employed in the collection of sEVs including ultracentrifugation, size exclusion chromatography, and methods utilizing precipitation kits and bead kits[14]. Details of sEV collection have been described in the minimal information for studies of extracellular vesicles guidelines 2018 (MISEV2018)[15]. After their collection, sEVs have been evaluated by western blotting, ELISA, flow cytometry, and nano
Extracellular vesicles (EVs) include apoptotic vesicles, microvesicles, and exosomes. Small EVs (sEVs), or exosomes, are formed from early endosomes that are generated by endocytosis and subsequently mature into late endosomes. The late endosomes expand to form intraluminal membrane vesicles, also referred to as multivesicular bodies, which fuse with the plasma membrane and are released into extracellular space. These sEVs, or exosomes, are analyzed for diagnosis, pathogenesis, and therapy of various diseases including liver diseases.

Tracking analysis to study the expression of common sEVs proteins, such as tetraspanins, and to identify markers including lipids, proteins, and nucleic acids, such as miRNAs and lincRNAs. Although the aforementioned studies are in the pre-clinical stage, they are expected to yield specific markers that can aid the processes of early and definitive diagnosis, treatment, and follow-up of liver diseases, in addition to helping in the elucidation of the pathophysiology governing many of these liver disorders. Table 1 summarizes the various liver diseases and their related sEVs diagnostic markers. The bulk of the studies reported on miRNAs as sEVs diagnostic biomarkers of liver diseases which may be due to the ease of evaluating them using qRT-PCR. Markers of HCC have been the most frequently analyzed, and diseases such as NASH and ALD have received the most attention in recent years. Extracting sEVs produced by target cells and using them as markers of disease can contribute greatly to the field of diagnosis and treatment of liver disorders. However, we believe that there are some limitations and challenges to be acknowledged and addressed in the future, such as the efficient collection of target sEVs, recognition of target molecules (e.g., protein miRNA), cost, and high reproducibility.

**Figure 1 Extracellular vesicles and liver diseases.** Extracellular vesicles (EVs) include apoptotic vesicles, microvesicles, and exosomes. Small EVs (sEVs), or exosomes, are formed from early endosomes that are generated by endocytosis and subsequently mature into late endosomes. The late endosomes expand to form intraluminal membrane vesicles, also referred to as multivesicular bodies, which fuse with the plasma membrane and are released into extracellular space. These sEVs, or exosomes, are analyzed for diagnosis, pathogenesis, and therapy of various diseases including liver diseases.

**BIODISTRIBUTION AND PHARMACOKINETICS OF sEVs**

Numerous studies have demonstrated the importance of the liver in the biodistribution and pharmacokinetics of sEVs. This has been accomplished by employing techniques such as lipophilic fluorescent and luminescent, radio-labeling, and magnetic resonance imaging. Studies have conclusively shown that post systemic administration of sEVs, these vesicles are cleared from the bloodstream within a few minutes of their half-life via phagocytosis by macrophages and neutrophils. While they disappear from the blood, they have been reported to persist longer within organs, with the largest accumulation occurring in the liver. This accumulation peaks in the liver and kidneys approximately 1 h post administration, which is earlier than that in the lungs where maximal accumulation is achieved 2–12 h post administration. It has been shown that high concentrations of sEVs can be maintained in the liver for about 12-24 h, although there have been contradictory reports about this. Some studies suggest that the macrophages primarily take up scaffold in the liver, while others report that hepatocytes and other cells also do the same. The abundant expression of scavenger receptors in macrophages is thought to play a crucial role in this process. Additionally, phosphatidyl serine (PS) has been found to easily accumulate in the liver unlike the phosphatidylcholine-rich lipids. Hoshino et al have demonstrated the importance of integrins by showing that integrin αvβ5 in sEVs is essential for its accumulation in macrophages. However, results from these studies must be interpreted with caution since most of them employed the technique of labeling lipid bilayers, which may have resulted in the
sEVs AND LIVER PATHOGENESIS

Many reports described the implication of sEVs in various aspects of the pathogenesis of liver diseases. These entities are highly stable in vivo and play an important role in the communication between both neighboring and distant cells. Table 2 summarizes the different sEV markers that have been linked to certain processes of liver pathogenesis.

sEVs exert their effect on inter-cellular communication between neighboring cells via the perisinusoidal space. For instance, it has been reported that sEVs secreted by HCV-infected hepatocytes exert an effect on hepatic stellate cells (HSCs) driving hepatic fibrosis. Additionally, as shown in Table 2, sEVs produced by hepatocellular carcinoma (HCC) have a profound effect on the surrounding environment. This effect is mediated by the modulation of the immune system by sEVs that have an inhibitory effect on macrophages, monocytes, NK cells, B cells, and T cells. These vesicles can also promote HSC and the transformation of fibroblasts to cancer-associated fibroblasts (CAFs), promote migration of hepatocellular carcinoma cells in the vicinity, act on vascular endothelial cells to promote angiogenesis, and induce drug resistance in surrounding cancer cells. Additionally, sEVs released from hepatocytes are believed to function as drivers of inflammation and state formation in inflammatory cells such as macrophages in NASH.
**Table 2 Small extracellular vesicles markers in relation to liver pathogenesis**

| Pathophysiology                      | Types of molecules | Markers                                                                 | Refs.     |
|---------------------------------------|--------------------|--------------------------------------------------------------------------|-----------|
| NASH inflammation and fibrosis        | miRNA              | miR-122, -192                                                           | [75]      |
| NASH fibrosis                         | miRNA              | miR-122                                                                 | [76]      |
| ALD outcome                           | protein            | ASGR2 and CYP2E1                                                        | [58]      |
| HBV fibrosis                          | miRNA              | miR-150, -192, -200b, -91a                                               | [77]      |
| HCV treatment response                 | miRNA              | miR-122, -199a, miR-122, miR-122-5p, -222-3p, -146-5p, -150-5p, -30c-5p, -378a-3p, -20a-5p | [53,78,79]|
| HCV fibrosis                          | protein            | CD81                                                                    | [80]      |
|                                        | miRNA              | Let-7s, miR-122, -150, -192, 200b, 92a, miR-19a                          | [77,81]   |
| HCC recurrence                        | protein            | SMAD3, CASC9                                                            | [16,92]   |
|                                        | RNA                | miR-718, miR-125, miR-21, miR-103, miR1247-3p, miR-92b, miR-21 and IncRNA-ATB, miR-21, -10b, miR-215-5p, miR-155, mRNA RAB11A, miR-211-3p, -6826-3p, -1226-3p, 4448 | [25,26,36,42,83-90]|
| HCC survival                          | RNA                | miR-125, miR-21, miR-103, miR-22a-3p, miR-335, miR-25-5p, miR-320-PBX3, miR-718, miR-210, miR-122, miR-95, miR-21, -96, -122, miR-1247-3p, miR-638, miR-665, miR-21 and IncRNA-ATB, miR-30d, -140, miR-106a, miR-224, miR-320d, long non-coding RNA (ENSG00000258332.1 and LINC00635), hnrNPH1, circPTGR1, circRNA-100, -338, circ DB | [18,23,31,32,34,36,38,41,43,82-86,88,91-99]|

NASH: Nonalcoholic steatohepatitis; ALD: Alcoholic liver disease; HBV: Hepatitis B virus; HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma; RNA: Ribonucleic acid; ASGR: Asialoglycoprotein receptor; CYP: Cytochrome P450; CD: Cluster of differentiation; SMAD: Suppressor of Mothers against Decapentaplegic; CASC: Cancer Susceptibility; PBX: Pre-B cell leukemia homeobox; Inc: long non-coding; ATR: Activated By TGF-Beta; ENSG: Ensemble Gene ID; LINC: Long intergenic noncoding; RNPH: Ribonucleoprotein H; PTGR: Prostaglandin Reductase; DB: Deubiquitination.

It has also been also reported that these vesicles drive the pathogenesis of disease through an effect on distant cells. This is exemplified by the crosstalk between the sEVs produced by adipocytes and those produced by hepatocellular carcinoma cells, which contributes to cell proliferation, angiogenesis, invasion, epithelial-mesenchymal transition, and the creation of a favorable environment for metastasis [103]. Recent reports have also demonstrated that microbiota-derived EVs in the intestine affect other organs and tissues in the body, including the liver, heart, brain, kidney, lung, and adipose tissue[104]. Though there have been some studies describing the effects of sEVs on various cells in the body, it is still unclear how these sEVs that are produced by specific cells selectively reach their target cells. Consequently, further analysis from a broader perspective is essential to describe the specificities and dynamics of this interaction between sEVs and their target cells.

**sEVs AND THE TREATMENT OF LIVER DISEASES**

To date, there have been no reports or ongoing trials on the application of sEVs in the treatment of liver diseases. This scarcity might be attributed to the fact that there are still many unknowns regarding the effects of sEVs on liver disease, but further mechanistic analysis in the future may lead to the development of new therapies. However, the potential of sEVs as anti-fibrotic and anti-cancer therapeutic agents needs to be explored. In the case of anti-fibrotic therapy, sEVs may be the most convenient therapeutic agents that target macrophages on account of their massive accumulation in these cells within the liver[5,105]. Furthermore, Mesenchymal stem (stromal) cells (MSCs) have been investigated for their anti-fibrotic properties due to their ability to suppress fibrogenesis by reducing the inflammatory responses of inflammatory cells and by inducing fibrolysis via their effect on macrophages and matrix metalloproteinases[106].

Basic research has recently revealed that sEVs secreted by MSCs transmit information to macrophages. Additionally, the potency of these sEVs has been enhanced by pre-conditioning the MSCs with IFN-γ to augment their therapeutic effects in a mouse model of liver cirrhosis[105]. In view of this, it might be possible to create and evaluate a therapeutic strategy that employs sEVs obtained from pre-conditioned or modified MSCs to transmit information to macrophages and exert anti-fibrotic effects suppressing fibrogenesis. Although such attempts have been made, the production of sEVs from pre-conditioned/modified MSCs has not yet been successful due to regulatory concerns, lack of appropriate quality control, and difficulties associated with mass purification.
Warnecke et al[107] reported a first-in-human case study that utilized MSC-EVs derived from umbilical cord tissues to reduce inflammation during cochlear implantation. Briefly, the authors obtained $1.03 \times 10^{11}$ particles/mL of EVs with a diameter range of 110–130 nm, as measured by nanoparticle tracking analysis, via a combination of tangential flow filtration (TFF) and diafiltration techniques post culture. This showed that MSC-derived exosomes may find successful application in clinical use. Furthermore, improvements in the methods that can reduce the quantity of exosomes needed for efficient treatment will further expedite their use in clinical scenarios[107].

The development of cancer therapies that employ sEVs are also theoretically possible, such as those that aim to suppress sEVs derived from cancer cells. Mendt et al[108] have developed a therapeutic strategy for pancreatic cancer using sEVs that is currently under clinical trials. Their study involved the optimization of iExosomes to enable them to deliver higher concentrations of sEVs to pancreatic cancers via a two-pronged strategy. This includes the selection of CD47 that protects exosomes from phagocytosis by macrophages and engineering exosomes to carry siRNA or shRNA specifically targeted against the oncogenic KRASG12D, the key driver of pancreatic cancer. The study also reported the feasibility of large-scale production of clinical grade iExosomes by a bioreactor-based methodology[108, 109]. Therefore, sEVs have a promising potential in anti-fibrotic and anti-cancer therapy, and their applications may be expanded by developing techniques that efficiently load therapy enhancing substances, aid their incorporation into target cells, and improve high-throughput collection methodologies.

CONCLUSION

In summary, small extracellular vesicles (sEVs) have a promising potential in the diagnosis and treatment of liver diseases. The challenge in the therapeutic uses of sEVs is that it is not easy to harvest large amount of sEVs for human systemic therapy. However, the collection of sEVs can be greatly enhanced by pre-conditioning or modifying the source cells, thereby greatly expanding their possible applications. Furthermore, the potential for using EVs in therapy may be enhanced by utilizing larger EVs in addition to sEVs. These vesicles can potentially be harvested from cell sources other than mesenchymal stem cells (MSCs), such as induced pluripotent stem cells (iPS cells). In addition, with using these larger EVs there are fewer risk of embolization especially to the lungs after the administration. Consequently, in spite of issues with future regulatory trends and establishment of manufacturing processes, sEVs remain a promising therapeutic option for liver ailments.

FOOTNOTES

Author contributions: Tsuchiya A collected and analyzed the data and wrote the manuscript; Natsui K, Ishii Y, Koseki Y, Takeda N, Tomiyoshi K, Yamazaki F, and Yoshida Y collected the data; Terai S supervised the manuscript; and All authors reviewed the manuscript.

Conflict-of-interest statement: All authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: Japan

ORCID number: Atsunori Tsuchiya 0000-0002-9279-5917; Kazuki Natsui 0000-0003-1988-4144; Yui Ishii 0000-0002-8514-7137; Yohei Koseki 0000-0002-2338-0830; Nobutaka Takeda 0000-0001-5440-8544; Kei Tomiyoshi 0000-0003-0148-9664; Fusako Yamazaki 0000-0002-0287-5244; Yuki Yoshida 0000-0001-9336-7220; Shuji Terai 0000-0002-5439-635X.

S-Editor: Ma YJ
L-Editor: A
P-Editor: Ma YJ

REFERENCES

1 Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science 2020; 367 [PMID: 32029601 DOI: 10.1126/science.aau6977]
2 Othman N, Jamal R, Abu N. Cancer-Derived Exosomes as Effectors of Key Inflammation-Related Players. Front
Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper.

B. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper.
Tsuchiya A et al. Small extracellular vesicles/liver/diagnosis/therapy

Ostrowski M, Park J, Pegtel DM, Peinado H, Perut F, Pfaffl MW, Phinney DG, Pieterse BC, Pink RC, Putsgets DS, Poigge von Strandmann E, Polakovičová I, Poon IK, Powell BH, Prada I, Pulliam L, Quesenberry P, Radeghieri A, Raffl RL, Raimondo S, Rak J, Ramírez MI, Raposo G, Rayyan MS, Regev-Rudzki N, Rickles FL, Robbins PD, Roberts DD, Rodrigues SC, Rohde E, Rome S, Roushop KM, Rughetti A, Russell AE, Saa P, Sahoo S, Salas-Huamelio E, Sanchez C, Saugstad JA, Saul MJ, Schifflers RM, Schneider R, Scheyni TH, Scott A, Shahaj E, Sharma S, Shatnaveya O, Shekari F, Shelke GV, Shetty AK, Shiba K, Slidjander PR, Silva AM, Skowronek A, Snyder JL, Soares ND, Someren AE, Song KS, Stoolmiller ER, Strasser E, Swift SJ, Tahara H, Tewari M, Timms K, Triwari S, Tixiera R, Tkach T, Toh WS, Tomasini R, Torrecillas AC, Tosap J, Toxavidis V, Urbanelli L, Vader P, van Balkom BW, van der Grein SG, Van de Peer J, van Herwijnen MJ, Van Keuren-Jensen K, van Niel G, van Royen ME, van Wijnen AJ, Vascellaro MH, Vechetti IJ Jr, Veit TD, Vella JL, Velot É, Verweij FJ, Vestad B, Viñas JL, Visnovitz T, Vukman KV, Wahlgren J, Watson DC, Wauben MH, Weaver A, Webber JP, Weber V, Wehman AM, Weiss DJ, Welsh JA, Wendt S, Wheelock A, Wiener Z, Witte L, Wolfram J, Xagorari A, Xander P, Xu J, Yan X, Yáñez-Mó M, Yin H, Yuana Y, Zappulli V, Zarubova J, Žėkas V, Zhang JY, Zhao Z, Zheng L, Zheutlin AR, Zickler AM, Zimmermann P, Zivkovic AM, Zocco D, Zuba-Surma EK. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 2017; 6: 1535750 [PMID: 30637094 DOI: 10.1002/1369-1076.12511]

Thietart S, Rautou PE. Exosomal vesicles as biomarkers in liver diseases: A clinician's point of view. J Hepatol 2020; 73: 1507-1525 [PMID: 32682050 DOI: 10.1016/j.jhep.2020.07.014]

Arbelaitz A, Azagargorta M, Krawczyk M, Santos-Laso A, Lapitz A, Perugorria MJ, Erice O, Gonzalez E, Jimenez-Agüero R, Lacasta A, Ibarra C, Sanchez-Campos A, Jimeno JP, Lammert F, Milukiewicz P, Marzioni M, Macias RIR, Marin JKG, Patel T, Gores GJ, Martinez I, Elortza F, Falcon-Perez JM, Bujanda L, Banales JM. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Hepatology 2017; 66: 1125-1143 [PMID: 28855885 DOI: 10.1002/hep.29291]

Wang Y, Functional biomarker in hepatocellular carcinoma. Minerva Med 2016; 107: 494, Identify Cirrhotic Patients with HCC.

Zuwała-Jagiełło J, Brandon-Warner E, Ferracin M, Trerè D, Milazzo M, Galassi M, Venerandi L, Pollutri D, Patrizi C, Borghi A, Foschi FG, Stefanini GF, Negriani M, Bolondi L, Gramantieri L. Circulating microRNAs, miR-939, miR-595, miR-519d and miR-3265p, as a Potential Diagnostic Biomarker for Early-Stage Hepatocellular Carcinoma. J Clin Med 2020; 9: 282-292 [PMID: 32627620 DOI: 10.1007/s41796-017-0202-4]

Wang S, Chen X, Shen H, Zhangyuan G, Huang R, Zhang W, He Q, Jin K, Zhao H, Zhang W, Sun B, Lu X. 14-3-3ζ delivered by hepatocellular carcinoma-derived exosomes impaired anti-tumor function of tumor-infiltrating T lymphocytes. Cell Death Dis 2018; 9: 159 [PMID: 29415983 DOI: 10.1038/s41419-017-0180-7]

Han Q, Lv L, Wei J, Lei X, Lin H, Li J, Cao J, Xie J, Yang W, Wu W, Su Y, You J, Liu J, Min J. Vps4A mediates the localization and exosome release of β-catenin to inhibit epithelial-mesenchymal transition in hepatocellular carcinoma. Cancer Lett 2019; 457: 47-59 [PMID: 31059752 DOI: 10.1016/j.canlet.2019.04.035]

Cheng Z, Lei Z, Yang P, Si A, Xiang D, Tang X, Guo G, Zhou J, Hüser N. Exosome-transmitted p120-catenin suppresses hepatocellular carcinoma progression via STAT3 pathways. Mol Carcinog 2019, 58: 1389-1399 [PMID: 30997702 DOI: 10.1002/mc.23022]

Julič-Haertel H, Urban SK, Krawczyk M, Willms A, Jankowski K, Patkowski W, Kruk B, Krasnodębski M, Ligocka J, Schwab R, Richardsen I, Schaaft S, Klein A, Gehlert S, Sänger H, Casper M, Banales JM, Schuppan D, Milukiewicz P, Lammert F, Lukac-kornel V, Kornel M. Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma. J Hepatol 2017; 67: 282-292 [PMID: 28627620 DOI: 10.1002/hep.29291]

Wang H, Hou L, Li A, Duan Y, Gao H, Song X. Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. Biomed Res Int 2014; 2014: 864894 [PMID: 24963487 DOI: 10.1155/2014/864894]

Wang S, Yang Y, Sun L, Qiao G, Song Y, Liu B. Exosomal MicroRNAs as Liquid Biopsy Biomarkers in Hepatocellular Carcinoma. Onco Targets Ther 2020, 13: 2021-2030 [PMID: 32210570 DOI: 10.2147/OTT.S322453]

Sohn W, Kim J, Kang SH, Yang SR, Cho JY, Cho HC, Shim SG, Paik YH. Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma. Exp Mol Med 2015; 47: e184 [PMID: 26380927 DOI: 10.1038/emm.2015.68]

Cho HJ, Eun JW, Baek GO, Seo CW, Ahn HR, Kim SS, Cho SW, Cheong JY. Serum Exosomal MicroRNA, miR-10b-5p, as a Potential Diagnostic Biomarker for Early-Stage Hepatocellular Carcinoma. J Clin Med 2020; 9: 31986858 DOI: 10.3390/jcm90100821]

Fornari F, Ferracin M, Tréré D, Milazzo M, Marinelli S, Galassi M, Venerandi L, Pollutri D, Patrizi C, Borgi A, Foschi FG, Stefanini GF, Negriani M, Bolondi L, Gramantieri L. Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC. PLoS One 2015; 10: e0141448 [DOI: 10.1371/journal.pone.0141448]

Brandon-Warner E, Feilen NA, Calberson CR, Field CO, deLemos AS, Russo MW, Schrum LW. Processing of miR17-92 Cluster in Hepatic Stellate Cells Promotes Hepatic Fibrogenesis During Alcohol-Induced Injury. Alcohol Clin Exp Res Exp 2016; 40: 1430-1442 [PMID: 27291156 DOI: 10.1111/acer.13116]

Zuwała-Jagiełło J, Simon KA, Pazgan-Simon M. Elevated circulating endothelial cell-derived microparticle levels in patients with liver cirrhosis: a preliminary report. Clin Hepatol 2015; 1: 105-111 [PMID: 28856256 DOI: 10.1111/ceh.2015.55567]

Tang J, Li Y, Liu K, Zhu Q, Yang WH, Xiong LK, Guo DL. Exosomal miR-9-3p suppresses HBGF-5 expression and is a functional biomarker in hepatocellular carcinoma. Minerva Med 2018; 109: 15-23 [PMID: 28750499 DOI: 10.23736/S0026-4806.17.05167-9]

Wang Y, Zhang C, Zhang P, Guo G, Jiang T, Zhao X, Jiang J, Huang X, Tong H, Tian Y. Serum exosomal microRNAs combined with alpha-fetoprotein as diagnostic markers of hepatocellular carcinoma. Cancer Med 2018; 7: 1670-1679 [PMID: 29573235 DOI: 10.1002/cam4.1390]

Suehiro T, Miyakki H, Kanda Y, Shibata H, Honda T, Ozawa E, Miuwa S, Taura N, Nakao K. Serum exosomal
microRNA-122 and microRNA-21 as predictive biomarkers in transarterial chemoembolization-treated hepatocellular carcinoma patients. *Oncof Lett* 2018; 16: 3267-3273 [PMID: 30127924 DOI: 10.3892/ol.2018.8991]

32 Xue X, Wang X, Zhao Y, Hu R, Qin L. Exosomal miR-93 promotes proliferation and invasion in hepatocellular carcinoma by directly inhibiting TIMP2/TP53INP1/CDKN1A. *Biochem Biophys Res Commun* 2018; 502: 515-521 [PMID: 29859933 DOI: 10.1016/j.bbrc.2018.05.028]

33 Pu C, Huang H, Wang Z, Zou W, Ly Y, Zhou Z, Zhang Q, Qiao L, Wu F, Shao S. Extracellular Vesicle-Associated miR-21 and mir-144 Are Markedly Elevated in Serum of Patients With Hepatocellular Carcinoma. *Front Physiol* 2018; 9: 930 [PMID: 30965664 DOI: 10.3389/fphys.2018.00930]

34 Liu XJ, Fang JH, Yang XJ, Zhang C, Yuan Y, Zheng L, Zhaung SM. Hepatocellular Carcinoma Cell-Secreted Exosomal MicroRNA-210 Promotes Angiogenesis In Vitro and In Vivo. *Mol Ther Nucleic Acids* 2018; 11: 243-252 [PMID: 29858058 DOI: 10.1016/j.omtn.2018.02.014]

35 Shi M, Jiang Y, Yang L, Yan S, Wang YG, Lu XJ. Decreased levels of serum exosomal miR-638 predict poor prognosis in hepatocellular carcinoma. *J Cell Biochem* 2018; 119: 4711-4716 [PMID: 29287659 DOI: 10.1002/jcb.26650]

36 Abdul El Gwad A, Matboli M, El-Tawdi A, Habib EK, Shehata H, Ibrahim D, Tash F. Role of exosomal competing endogenous RNA in patients with hepatocellular carcinoma. *J Cell Biochem* 2018; 119: 8600-8610 [PMID: 30015383 DOI: 10.1002/jcb.27109]

37 Wang G, Zhao W, Wang H, Qiu G, Jiang Z, Wei G, Li X. Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2. *Med Sci Monit* 2019; 25: 7209-7217 [PMID: 31553714 DOI: 10.12659/MSM.919219]

38 Li W, Ding X, Wang S, Xu L, Yin T, Han S, Geng J, Sun W. Downregulation of serum exosomal miR-882-3p predicts poor prognosis in hepatocellular carcinoma. *J Clin Lab Anal* 2020; 34: e23239 [PMID: 32125733 DOI: 10.1002/jcla.23239]

39 Liu Y, Tan J, Ou S, Chen J, Chen L. Adipose-derived exosomes deliver miR-23a/b to regulate tumor growth in hepatocellular cancer by targeting the VHL/HIF axis. *J Physiol Biochem* 2019; 75: 391-401 [PMID: 31321740 DOI: 10.1023/s13105-019-00962-4]

40 Zhao S, Li J, Zhang G, Wang Q, Wu C, Zhang Q, Wang H, Sun P, Xiang R, Yang S. Exosomal miR-451a Functions as a Tumor Suppressor in Hepatocellular Carcinoma by Targeting LPIN1. *Cell Physiol Biochem* 2019; 53: 19-35 [PMID: 31162914 DOI: 10.3389/fphys.2019.000118]

41 Cui Y, Xu HF, Liu MY, Xu YJ, He JC, Zhou Y, Cang SD. Mechanism of exosomal microRNA-224 in development of hepatocellular carcinoma and its diagnostic and prognostic value. *World J Gastroenterol* 2019; 25: 1890-1898 [PMID: 31057302 DOI: 10.3748/wjg.v25.i15.1890]

42 Tian XP, Wang CY, Jin XH, Li M, Wang FW, Huang WJ, Yun JP, Xu RH, Cai QQ, Xie D. Acidic Microenvironment Up-Regulates Exosomal miR-21 and miR-10b in Early-Stage Hepatocellular Carcinoma to Promote Cancer Cell Proliferation and Metastasis. *Theranostics* 2019; 9: 1965-1979 [PMID: 31037150 DOI: 10.7150/thno.30958]

43 Xue X, Zhao Y, Wang X, Qin L, Hu R. Development and validation of serum exosomal microRNAs as diagnostic and prognostic biomarkers for hepatocellular carcinoma. *J Cell Biochem* 2019; 120: 135-142 [PMID: 30238497 DOI: 10.1002/jcb.27115]

44 Lin H, Zhang Z. Diagnostic value of a microRNA signature panel in exosomes for patients with hepatocellular carcinoma. *Int J Clin Exp Pathol* 2019; 12: 1478-1487 [PMID: 3193969]

45 Ma X, Yuan T, Yang C, Wang Z, Zang Y, Wu L, Zhaung L. X-inactive-specific transcript of peripheral blood cells is regulated by exosomal Jpx and acts as a biomarker for female patients with hepatocellular carcinoma. *Ther Adv Med Oncol* 2017; 9: 665-677 [PMID: 29344104 DOI: 10.1177/1758834017731052]

46 Li B, Mao R, Liu C, Zhang W, Tang Y, Guo Z. lncRNA FAL1 promotes cell proliferation and migration by acting as a CeRNA of miR-1236 in hepatocellular carcinoma cells. *Life Sci* 2018; 197: 122-129 [PMID: 29421439 DOI: 10.1016/j.lfs.2018.02.066]

47 Zhang C, Yang X, Qi Q, Gao Y, Wei Q, Han S. lncRNA-HEIH in serum and exosomes as a potential biomarker in the HCV-related hepatocellular carcinoma. *Cancer Biomark* 2018; 21: 651-659 [PMID: 29286922 DOI: 10.3233/CBM-170727]

48 Sun L, Su Y, Liu X, Xu M, Chen X, Zhy Y, Guo Z, Bai T, Dong L, Wei C, Cai X, He B, Pan Y, Sun H, Wang S. Serum and exosome long non coding RNAs as potential biomarkers for hepatocellular carcinoma. *J Cancer* 2019; 8: 2631-2639 [PMID: 30087703 DOI: 10.7150/jca.24978]

49 Cao SQ, Zheng H, Sun BC, Wang ZL, Liu T, Guo DH, Shen ZY. Long non-coding RNA highly up-regulated in liver cancer promotes exosome secretion. *World J Gastroenterol* 2019; 25: 5283-5299 [PMID: 31558873 DOI: 10.3748/wjg.v25.i15.5283]

50 Wang X, Kwak KJ, Yang Z, Zhang A, Zhang X, Sullivan R, Lin D, Lee RL, Castro C, Ghoshal K, Schmidt C, Lee LJ. Extracellular miRNA detected by molecular beacon in tethered lipoplex nanoparticles for diagnosis of human hepatocellular carcinoma. *PLoS One* 2018; 13: e0198552 [PMID: 29879168 DOI: 10.1371/journal.pone.0198552]

51 Liu Z, Zhang X, Yu Q, He JJ. Exosome-associated hepatitis C virus in cell cultures and patient plasma. *Biochem Biophys Res Commun* 2014; 455: 218-222 [PMID: 25499270 DOI: 10.1016/j.bbrc.2014.10.146]

52 Bukong TN, Momen-Heravi F, Kody K, Bala S, Szabo G. Exosomes from hepatitis C infected patients transmit HCV infection and contain replication competent viral RNA in complex with Agoe-miR122-HSP90. *PLoS Pathog* 2014; 10: e1004424 [PMID: 25275643 DOI: 10.1371/journal.ppat.1004424]

53 Santangelo L, Bordoni V, Montaldo C, Cimini E, Zongini A, Battistelli C, D'Ottizi G, Capobianchi MR, Santoni A, Triiopido M, Agrati C. Hepatitis C virus direct-acting antivirals therapy impacts on extracellular vesicles microRNAs content and on their immunomodulating properties. *Liver Int* 2018; 38: 1741-1750 [PMID: 29359380 DOI: 10.1111/liv.13700]

54 Guo Q, Furuta K, Lucien F, Gutierrez Sanchez LH, Hirsova P, Krishnan A, Kabashima A, Pavelko KD, Madden B, Alnuwaish H, Gao Y, Revzin A, Ibrahim SH. Integrin β3-enriched extracellular vesicles mediate monocyte adhesion and promote liver inflammation in murine NASH. *J Hepatol* 2019; 71: 1193-1205 [PMID: 31433301 DOI: 10.1016/j.jhep.2019.07.019]
Um SH, Byun KS. Exosomes derived from palmitic acid-treated hepatocytes induce fibrotic activation of hepatic stellate cells. *J Lipid Res* 2016; 57: 233-245 [DOI: 10.1194/jlr.M063412]

Schein T, Aram JP, Liu M, Amrollahi P, Wan M, Fan J, Nakao Y, Pose E, Navarro-Coreuera A, Dasgupta D, Liao CY, He L, Maurer AS, Avitabile E, Ventura-Cots M, Bataller RA, Sanjay AJ, Chalasani NP, Heimbach JK, Watt KD, Gores GJ, Gines P, Camath PS, Simonetto DA, Hu TY, Shah VH, Malhi H. Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis. *Hepatology* 2021; 73: 571-585 [PMID: 32246544 DOI: 10.1002/hep.31256]

Nielsen MC, Andersen MN, Gronbak H, Damgaard Sandahl T, Moller HJ. Extracellular vesicle-associated soluble CD163 and CD206 in patients with acute and chronic inflammatory liver disease. *Scand J Gastroenterol* 2020; 55: 588-596 [PMID: 32393080 DOI: 10.1080/0033512520.201759140]

Verma VK, Li H, Wang R, Hirsova P, Mushref M, Liu Y, Cao S, Contreras PC, Malhi H, Kamath PS, Gores GJ, Shah VH. Alcohol stimulates macrophage activation through caspase-dependent hepatocyte derived release of CD40L containing extracellular vesicles. *J Hepatol* 2016; 64: 651-660 [PMID: 26623633 DOI: 10.1016/j.jhep.2015.11.020]

Bissonnette J, Altamirano J, Devue C, Roux O, Payanec A, Lebrecc D, Bedossa P, Valla D, Durand F, Ait-Oufella H, Sancho-Bru P, Caballeria J, Ginés P, Boulanger CM, Bataller R, Rautou PE. A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis. *Hepatology* 2017; 66: 555-563 [DOI: 28120471 DOI: 10.1002/hep.29080]

Cho YE, Im EJ, Moon PG, Mezey E, Song BJ, Baek MC. Increased liver-specific proteins in circulating extracellular vesicles as potential biomarkers for drug- and alcohol-induced liver injury. *PLoS One* 2017; 12: e0172463 [PMID: 28225070 DOI: 10.1371/journal.pone.0172463]

Momen-Heravi F, Bala S, Kodys K, Szabo G. Exosomes derived from alcohol-treated hepatocytes horizontally transfer liver specific mRNA-122 and sensitize monocytes to LPS. *Sci Rep* 2015; 5: 9991 [DOI: 10.1038/srep09991]

Ueguchi A, Lazaro RG, Wang J, Kim J, Povero D, Williams B, Ho SB, Stärkel P, Schnabl B, Ohno-Machado L, Tsukamoto H, Feldstein AE. Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood. *Hepatology* 2017; 65: 475-490 [PMID: 27639178 DOI: 10.1002/hep.28838]

Ueguchi A, Franz N, Kobayashi Y, Iawa M, Wagner N, Hildebrand F, Takei Y, Marzi I, Relja B. Circulating Extracellular Vesicles and Their miR "Barcode" Differentiate Alcohol Drinkers With Liver Injury and Those Without Liver Injury in Severe Trauma Patients. *Front Med (Lausanne)* 2019; 6: 30 [PMID: 30859103 DOI: 10.3389/fmed.2019.00030]

Momen-Heravi F, Saha B, Kodys K, Catalano D, Satischchandran A, Szabo G. Increased number of circulating exosomes and their microRNA cargos are potential novel biomarkers in alcoholic hepatitis. *J Transl Med* 2015; 13: 261 [PMID: 26264599 DOI: 10.1186/s12967-015-0623-9]

Wang R, Ding Q, Yaqoob U, de Assunciao TM, Verma VK, Hirsova P, Cao S, Mukhopadhyay D, Huebert RC, Shah VH. Exosome Adherence and Internalization by Hepatic Stellate Cells Triggers Sphingosine 1-Phosphate-dependent Migration. *J Biol Chem* 2015; 290: 30684-30696 [PMID: 26534962 DOI: 10.1074/jbc.M115.671735]

Kostallari E, Hirsova P, Prasnacka A, Verma VK, Yaqoob U, Wongjarupong N, Roberts LR, Shah VH. Hepatic stellate cell-derived platelet-derived growth factor receptor-alpha-enriched extracellular vesicles promote liver fibrosis in mice through SHP2. *Hepatology* 2018; 68: 333-348 [PMID: 29360139 DOI: 10.1002/hep.29031]

Lambrecht J, Verhulst S, Mannenerts I, Sowa JP, Best J, Canbay A, Reynaert H, van Grunsven LA. A PDGFβR-based score predicts significant liver fibrosis in patients with chronic alcohol abuse, NAFLD and viral liver disease. *EBioMedicine* 2019; 43: 501-512 [PMID: 31036530 DOI: 10.1016/j.ebiom.2019.04.036]

Awdisu L, Tundosa S, Pearlman M, Kokoy-Mondragon C, Ghassemian M, Naviaux RK, Patton HM, Mehta RL, Vijay B, RamachandraRao SP. Identification of Hepatic Glucomucolase as a Biomarker of Acute Kidney Injury in Patients with Cirrhosis. *Crit Care Res Pract* 2019; 2019: 5912804 [DOI: 10.1155/2019/5912804]

Royo F, Schlangen K, Palomo L, Gonzalez E, Conde-Vancells J, Berisa A, Aransay AM, Falcon-Perez JM. Transcriptome of extracellular vesicles released by hepatocytes. *PLoS One* 2013; 8: e86893 [DOI: 10.1371/journal.pone.0068693]

Choi H, Choi Y, Yim HY, Mirzaaghaei A, You JK, Choi C. Biodistribution of Exosomes and Engineering Strategies for Targeted Delivery of Therapeutic Exosomes. *Tissue Eng Regen Med* 2021; 18: 499-511 [PMID: 34260047 DOI: 10.1089/s13770-021-00361-0]

Kang M, Jordan V, Blenkiron C, Chamley LW. Biodistribution of extracellular vesicles following administration into animals: A systematic review. *J Extracell Vesicles* 2021; 10: e2085 [PMID: 33419469 DOI: 10.1080/2001-3745.2021.1923782]

Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesis Mark M, Molina H, Koolsak S, Di Giannattale A, Coder S, Singh S, Williams C, Slopop N, Urey K, Phummar L, King T, Bojmar L, Davies AE, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss JM, Dumont-Colle YD, Kramer W, Wexler LH, Narendran A, Schwartz GK, Healey JD, Sandstrom P, Labori KJ, Kure EH, Grandgenett PM, Hollingsworth MA, de Sousa M, Kaur S, Jain M, Mallya K, Batra SK, Jarnagin WR, Brady MS, Fodstad O, Muller V, Pantel K, Minn AJ, Bissell MJ, Garcia BA, Kang Y, Rajasekhar VK, Ghajar CM, Matei I, Peinado H, Bromberg J, Lyden D. Tumour exosome integrins determine organotropic metastasis. *Nature* 2015; 527: 329-335 [PMID: 26524530 DOI: 10.1038/nature15756]

Lee YS, Kim SY, Ko E, Lee JH, Yi HS, Yoo YJ, Je J, Suh SJ, Jung YK, Kim JH, Seo YS, Yim HJ, Jeong WI, Yeon JE, Um SH, Byun KS. Exosomes derived from palmitic acid-treated hepatocytes induce fibrotic activation of hepatic stellate cells. *Sci Rep* 2017; 7: 3710 [DOI: 10.1038/s41598-017-03389-2]
Clin Chem Lab Med

Xu H

Diagnosis and Prognosis of Hepatocellular Carcinoma.

Xu H

hepatocellular carcinoma patient-derived cell models.

Yu LX

10.18632/oncotarget.20881

Qu Z

prognostic marker for hepatocellular carcinoma.

Liu W

Biomedicines

Recurrence of Hepatocellular Carcinoma in Patients with Direct-Acting Antiviral-Induced Sustained Viral Response.

Akutsu T, Ochiya T, Kawada N, Murakami Y. Circulating Exosomal miRNA Profiles Predict the Occurrence and

from Hepatocellular Carcinoma Cells Under Hypoxia Promotes Angiogenesis in Endothelial Cells.

Asaoka T, Noda T, Kawamoto K, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M. Exosomal miR-155 Derived

Matsuura Y

1452 [PMID: 28077652] DOI: 10.1128/JVI.02225-16

Gramaniteri L, Baglioni M, Fornari F, Linigestra MA, Ferracin M, Indio V, Ravaiolli M, Cescon M, De Pace V, Leoni S, Coouda CA, Negri M, Bolondi L, Giovannini C. LncRNAs as novel players in hepatocellular carcinoma recurrence. Oncotarget 

2018; 9: 35085-35099 [PMID: 30416681] DOI: 10.18632/oncotarget.26202

Sugimachi K, Matsunuma T, Hirata H, Uchi R, Ueda M, Ueo H, Shidem Y, Iguchi T, Eguchi H, Shirabe K, Ochiya T, Machara Y, Mimirori K. Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation. Br J Cancer 

2015; 112: 532-538 [PMID: 25584485] DOI: 10.1038/bjc.2014.621

Zhou Y, Ren H, Dai B, Li J, Shang I, Huang J, Shi X. Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts. J Exp Clin Cancer Res 

2018; 37: 324 [PMID: 30591064] DOI: 10.1186/s13046-018-0965-6

Fang JH, Zhang ZJ, Shang LR, Luo YW, Lin YF, Yuan Y, Zhanmga SM. Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins. Hepatology 

2018; 68: 1459-1475 DOI: 10.1002/hep.29290

Fang T, Lv H, Lv G, Li T, Wang C, Han Q, Yu L, Su B, Guo L, Huang S, Cao D, Tang L, Tang S, Wu M, Yang W, Wang H. Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nat Commun 

2018; 9: 191 [PMID: 29335537] DOI: 10.1038/s41467-017-02583-0

Nakano T, Chen IH, Wang CC, Chen PJ, Tseng HP, Huang KT, Hu TH, Li LC, Goto S, Cheng YF, Lin CC, Chen CL. Circulating exosomal miR-92b: Its role for cancer immunomodulating and clinical value for prediction of posttransplant hepatocellular carcinoma recurrence. An J Transplant 

2019; 19: 3250-3262 [PMID: 31162867] DOI: 10.1111/ajt.15490

Lee YR, Kim G, Tak WY, Jang SY, Kweon YO, Park JG, Lee HW, Han YS, Chun JM, Park SY, Hur K. Circulating exosomal noncoding RNAs as prognostic biomarkers in human hepatocellular carcinoma. Int J Cancer 

2019; 144: 1444-1452 [PMID: 30338550] DOI: 10.1002/ijc.31931

Matsuura Y, Wada H, Eguchi H, Gotoh K, Kobayashi S, Kinoshita M, Kubo M, Hayashi K, Iwagami Y, Yamada D, Asaoka T, Noda T, Kawamoto K, Takeda Y, Tanenura M, Umeshita K, Doki Y, Mori M. Exosomal miR-155 Derived From Hepatocellular Carcinoma Cells Under Hypoxia Promotes Angiogenesis in Endothelial Cells. Dig Dis Sci 

2019; 64: 792-802 [PMID: 30465177] DOI: 10.1007/s10620-018-5380-1

Itami-Matsuzo M, Hayakawa M, Uchida-Kobayashi S, Enomoto M, Tamori A, Mizuno K, Toyoda H, Tamura T, Akutsu T, Ochiya T, Kawada N, Murakami Y. Circulating Exosomal miRNA Profiles Predict the Occurrence and Recurrence of Hepatocellular Carcinoma in Patients with Direct-Acting Antiviral-Induced Sustained Viral Response. Biomedicines 

2019; 7 [PMID: 31684167] DOI: 10.3390/biomedicines7040087

Liu W, Hu J, Zhou K, Chen F, Wang Z, Liao B, Dai Z, Cao Y, Fan J, Zhou J. Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma. Oncoto Targets Ther 

2017; 10: 3834-3851 [PMID: 28814883] DOI: 10.2147/OTT.S140062

Liu J, Fan L, Yu H, Zhang J, He Y, Feng D, Wang F, Li X, Liu Q, Li Y, Guo Z, Gao B, Wei W, Wang H, Sun G. Endolysosomal Reticular Stress Causes Liver Cancer Cells to Release Exosomal miR-23a-3p and Up-regulate Programmed Death Ligand 1 Expression in Macrophages. Hepatology 

2019; 70: 241-258 [PMID: 30854665] DOI: 10.1002/hep.20607

Wang F, Li L, Pientek K, Sakaguchi M, Selaru FM. Exosome miR-335 as a novel therapeutic strategy in hepatocellular carcinoma. Hepatology 

2018; 67: 940-954 [PMID: 29023935] DOI: 10.1002/hep.29586

Qu Z, Wu J, Ji A, Qiang G, Jiang Y, Jiang C, Ding Y. Exosomal miR-665 as a novel minimally invasive biomarker for hepatocellular carcinoma diagnosis and prognosis. Oncotarget 

2017; 8: 80666-80876 [PMID: 29113334] DOI: 10.18632/oncotarget.20881

Yu LX, Zhang BL, Yang Y, Wang MC, Lei GL, Gao Y, Liu H, Xiao CH, Xu JX, Qin H, Xu XY, Chen ZS, Zhang DD, Li FG, Zhang SG, Liu R. Exosomal microRNAs as potential biomarkers for cancer cell migration and prognosis in hepatocellular carcinoma patient-derived cell models. Oncol Rep 

2019; 41: 257-269 [PMID: 30542726] DOI: 10.3892/or.2018.6829

Xu H, Chen Y, Dong X, Wang X. Serum Exosomal Long Noncoding RNAs ENST00000258332.1 and LINC00635 for the Diagnosis and Prognosis of Hepatocellular Carcinoma. Cancer Epidemiol Biomarkers Prev 

2018; 27: 710-716 [PMID: 29607888 DOI: 10.1158/1055-9965.EPI-17-0770]

Xu H, Dong X, Chen Y, Wang X. Serum exosomal hnRNPH1 mRNA as a novel marker for hepatocellular carcinoma. Clin Chem Lab Med 

2018; 56: 479-484 [PMID: 29252188 DOI: 10.1515/cclm-2017-0327]
Wang G, Liu W, Zou Y, Wang G, Deng Y, Luo J, Zhang Y, Li H, Zhang Q, Yang Y, Chen G. Three isoforms of exosomal circPTGR1 promote hepatocellular carcinoma metastasis via the miR449a-MET pathway. _EBioMedicine_ 2019; 40: 432-445 [PMID: 30630697 DOI: 10.1016/j.ebiom.2018.12.062]

Huang XY, Huang ZL, Huang J, Xu B, Huang XY, Xu YH, Zhou J, Tang ZY. Exosomal circRNA-100338 promotes hepatocellular carcinoma metastasis via enhancing invasiveness and angiogenesis. _J Exp Clin Cancer Res_ 2020; 39: 20 [PMID: 31973767 DOI: 10.1186/s13046-020-1529-9]

Khatun M, Ray RB. Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis. _Cells_ 2019; 8 [PMID: 31615075 DOI: 10.3390/cells8101249]

He R, Wang Z, Shi W, Yu L, Xia H, Huang Z, Liu S, Zhao X, Xu Y, Yam JWP, Cui Y. Exosomes in hepatocellular carcinoma microenvironment and their potential clinical application value. _Biomed Pharmaeconomics_ 2021; 138: 111529 [PMID: 34311529 DOI: 10.1016/j.biopharma.2021.111529]

Srinivas AN, Suresh D, Santhekadur PK, Suvarnia D, Kumar DP. Extracellular Vesicles as Inflammatory Drivers in NAFLD. _Front Immunol_ 2020; 11: 627424 [PMID: 33603757 DOI: 10.3389/fimmu.2020.627424]

Rios-Colon L, Arthur E, Niture S, Qi Q, Moore JT, Kumar D. The Role of Exosomes in the Crosstalk between Adipocytes and Liver Cancer Cells. _Cells_ 2020; 9 [PMID: 32872417 DOI: 10.3390/cells9091988]

Díaz-Garrido N, Badia J, Baldomá L. Microbiota-derived extracellular vesicles in interkingdom communication in the gut. _J Extracell Vesicles_ 2021; 10: e12161 [PMID: 34738337 DOI: 10.1002/jev2.12161]

Takeuchi S, Tsuchiya A, Iwasawa T, Nojiri S, Watanabe T, Ogawa M, Yoshida T, Fujiki K, Kou Y, Kido T, Yoshioka Y, Fujita M, Kikuta J, Itoh T, Takamura M, Shirahige K, Ishii M, Ochiya T, Terai S. Small extracellular vesicles derived from interferon-γ pre-conditioned mesenchymal stromal cells effectively treat liver fibrosis. _NPJ Regen Med_ 2021; 6: 19 [PMID: 33785758 DOI: 10.1038/s41536-021-00132-4]

Watanabe Y, Tsuchiya A, Seino S, Kawata Y, Kojima Y, Ikarashi S, Starkey Lewis PJ, Lu WY, Kikuta J, Kawai H, Yamagiwa S, Forbes SJ, Ishii M, Terai S. Mesenchymal Stem Cells and Induced Bone Marrow-Derived Macrophages Synergistically Improve Liver Fibrosis in Mice. _Stem Cells Transl Med_ 2019; 8: 271-284 [PMID: 30394698 DOI: 10.1002/sctm.18-0105]

Warnecke A, Pretzler N, Harre J, Köhl U, Gärtner L, Lenarz T, Laner-Plamberger S, Wietzorrek G, Staecker H, Lassacher T, Hollerweger J, Gimona M, Rohde E. First-in-human intracochlear application of human stromal cell-derived extracellular vesicles. _J Extracell Vesicles_ 2021; 10: e12094 [PMID: 34136108 DOI: 10.1002/jev2.12094]

Mendt M, Kamerkar S, Sugimoto H, McAndrews KM, Wu CC, Gagea M, Yang S, Blanko EVR, Peng Q, Ma X, Marszałek JR, Maitra A, Yee C, Rezvani K, Shpall E, LeBlue VS, Kalluri R. Generation and testing of clinical-grade exosomes for pancreatic cancer. _JCI Insight_ 2018; 3 [PMID: 29669940 DOI: 10.1172/jci.insight.99263]

Kamerkar S, LeBlue VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, Lee JJ, Kalluri R. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. _Nature_ 2017; 546: 498-503 [PMID: 28607485 DOI: 10.1038/nature22341]
